INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors in Lipocine Inc. of a Class Action Lawsuit & a Lead Plaintiff Deadlin...
August 19 2016 - 10:52AM
Business Wire
The following statement is being issued by Levi & Korsinsky,
LLP:
To: All persons or entities who purchased or otherwise
acquired securities of Lipocine Inc. (“Lipocine” or “the
Company”) (NASDAQ: LPCN) between June 30,
2015 and June 28, 2016. You are hereby notified
that a securities class action lawsuit has been commenced in the
USDC for the District of New Jersey. To get more information go
to:
http://www.zlk.com/pslra/lipocine-inc
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period,
defendants issued materially false and/or misleading statements
and/or failed to disclose that: (1) Lipocine’s filing of its New
Drug Application for LPCN 1021, Lipocine’s lead product candidate,
contained deficiencies; and (2) as a result, defendant’s statements
about Lipocine’s business and operations were false and misleading
and/or lacked a reasonable basis.
On June 29, 2016, Lipocine announced that the U.S. Food and Drug
Administration had issued a Complete Response Letter regarding the
Company’s New Drug Application for LPCN 1021. According to the
Complete Response Letter, the FDA has identified deficiencies
related to the dosing algorithm for the label and concluded the
application was not ready for approval in its present form.
If you suffered a loss in Lipocine you have until
August 30, 2016 to request that
the Court appoint you as lead plaintiff. Your ability to share in
any recovery doesn’t require that you serve as a lead
plaintiff.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation, and have recovered
hundreds of millions of dollars for aggrieved shareholders.
Attorney advertising. Prior results do not guarantee similar
outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160819005419/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq.Tel: (212)
363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Sep 2023 to Sep 2024